{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:55:14Z","timestamp":1794412514561,"version":"4.9.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1053\/j.gastro.2024.06.038","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T20:24:22Z","timestamp":1726086262000},"page":"1228-1238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review"],"prefix":"10.1053","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7214-5901","authenticated-orcid":false,"given":"Amit","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moayyedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2024.06.038_bib1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","article-title":"Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review","volume":"63","author":"El-Serag","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.06.038_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1053\/j.gastro.2021.10.017","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021","volume":"162","author":"Peery","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib4","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","article-title":"Proton pump inhibitor use: systematic review of global trends and practices","volume":"79","author":"Shanika","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2024.06.038_bib5","first-page":"693","article-title":"Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders","volume":"18","author":"Wong","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1053\/j.gastro.2024.06.038_bib6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.16295","article-title":"Review article: potassium-competitive acid blockers for the treatment of acid-related disorders","volume":"53","author":"Abdel-Aziz","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s10620-017-4866-6","article-title":"Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases","volume":"63","author":"Yang","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.06.038_bib8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2024.06.038_bib9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.gastro.2018.01.018","article-title":"Update on the use of vonoprazan: a competitive acid blocker","volume":"154","author":"Graham","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/j.gastro.2023.01.042","article-title":"American Gastroenterological Association membership policy priorities: building the American Gastroenterological Association advocacy agenda","volume":"164","author":"Patel","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.14309\/ajg.0000000000001728","article-title":"2021 National survey on prior authorization burden and its impact on gastroenterology practice","volume":"117","author":"Shah","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","article-title":"Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects","volume":"117","author":"Laine","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcph.1805","article-title":"Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects","volume":"61","author":"Ghim","year":"2021","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1053\/j.gastro.2024.06.038_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/apt.17406","article-title":"Randomised clinical trial: safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects","volume":"57","author":"Hwang","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/apt.14818","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects","volume":"48","author":"Sunwoo","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5009\/gnl220050","article-title":"Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study","volume":"17","author":"Han","year":"2023","journal-title":"Gut Liver"},{"key":"10.1053\/j.gastro.2024.06.038_bib18","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial","volume":"164","author":"Laine","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.15865","article-title":"Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer","volume":"52","author":"Cho","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib22","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.14309\/ajg.0000000000001309","article-title":"Potent acid suppression with vonoprazan vs proton pump inhibitors does not have higher association with Clostridioides difficile infection","volume":"116","author":"Watanabe","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/jgh.16169","article-title":"Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors","volume":"38","author":"Saruta","year":"2023","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.06.038_bib24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cgh.2024.01.037","article-title":"Association between vonoprazan and the risk of gastric cancer after Helicobacter pylori eradication","volume":"22","author":"Arai","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.06.038_bib25","article-title":"Re-evaluating the proposed association between vonoprazan and gastric cancer following eradication of H. pylori infection","author":"Howden","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.06.038_bib26","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(23)03775-7","article-title":"EP54 Final observation results of vision trial: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis","volume":"164","author":"Kinoshita","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib27","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1080\/00365521.2022.2097893","article-title":"Long-term changes in serum gastrin levels during standard dose vonoprazan therapy","volume":"57","author":"Shinozaki","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib28","doi-asserted-by":"crossref","first-page":"S-1066","DOI":"10.1016\/S0016-5085(22)62550-2","article-title":"EP1118: 4-year interim analysis results of vision trial: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis","volume":"162","author":"Kushima","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1136\/gutjnl-2016-313312","article-title":"Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals","volume":"66","author":"Otsuka","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.06.038_bib30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/jat.3607","article-title":"Embryo-fetal toxicity assessment of vonoprazan in rats and rabbits","volume":"38","author":"Li","year":"2018","journal-title":"J\u00a0Appl Toxicol"},{"key":"10.1053\/j.gastro.2024.06.038_bib31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/apt.15438","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"50","author":"Han","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib32","first-page":"305","article-title":"Diagnosis and management of refractory gastroesophageal reflux disease","volume":"17","author":"Patel","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1053\/j.gastro.2024.06.038_bib33","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/archinte.160.10.1455","article-title":"Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group","volume":"160","author":"Agrawal","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2024.06.038_bib34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole Versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group","volume":"338","author":"Hawkey","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.06.038_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","article-title":"Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study","volume":"81\u201382","author":"Kinoshita","year":"2016","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1053\/j.gastro.2024.06.038_bib36","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000101","article-title":"Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study","volume":"10","author":"Kinoshita","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/apt.16477","article-title":"Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease","volume":"54","author":"Kim","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.05.004","article-title":"Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial","author":"Laine","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.06.038_bib39","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/apt.17728","article-title":"Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease","volume":"58","author":"Fass","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","article-title":"Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs lansoprazole for the treatment of erosive oesophagitis","volume":"42","author":"Ashida","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apt.15185","article-title":"Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs esomeprazole in patients with erosive oesophagitis","volume":"49","author":"Lee","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.06.038_bib44","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/apt.16959","article-title":"The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study","volume":"55","author":"Chen","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib45","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.3748\/wjg.v28.i44.6294","article-title":"Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis","volume":"28","author":"Lee","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jgh.16471","article-title":"The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study","volume":"39","author":"Zhuang","year":"2024","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.06.038_bib47","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","article-title":"Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole","volume":"24","author":"Ashida","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/apt.17255","article-title":"Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis","volume":"57","author":"Cho","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib49","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2018.1144","article-title":"Gastroesophageal reflux monitoring","volume":"319","author":"Patel","year":"2018","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1053\/j.gastro.2024.06.038_bib50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12664-023-01384-2","article-title":"Vonoprazan versus lansoprazole in erosive esophagitis - a systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Chandan","year":"2023","journal-title":"Indian J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.gastro.2022.10.022","article-title":"Potassium-competitive acid blocker suppression of gastric acid in erosive esophagitis: is stronger and longer better?","volume":"164","author":"Katzka","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib52","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/gutjnl-2023-330616","article-title":"Updates to the modern diagnosis of GERD: Lyon Consensus 2.0","volume":"73","author":"Gyawali","year":"2024","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.06.038_bib53","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.14309\/ajg.0000000000000734","article-title":"ACG clinical guidelines: clinical use of esophageal physiologic testing","volume":"115","author":"Gyawali","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib54","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1053\/j.gastro.2022.06.076","article-title":"The current role of vonoprazan in Helicobacter pylori treatment","volume":"163","author":"Fallone","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib55","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1111\/jgh.16017","article-title":"A\u00a0comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis","volume":"37","author":"Simadibrata","year":"2022","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.06.038_bib56","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000632","article-title":"Comparative efficacy of tegoprazan vs esomeprazole\/sodium bicarbonate for the treatment of Helicobacter pylori infection","volume":"14","author":"Park","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.5009\/gnl220218","article-title":"Efficacy and tolerability of 14-day tegoprazan- versus rabeprazole-based triple therapy for eradication of Helicobacter pylori: a real-world evidence study","volume":"17","author":"Jung","year":"2023","journal-title":"Gut Liver"},{"key":"10.1053\/j.gastro.2024.06.038_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence Consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.06.038_bib59","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.06.038_bib60","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/apt.17070","article-title":"Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication","volume":"56","author":"Ang","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib61","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib62","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000504939","article-title":"Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line helicobacter pylori eradication therapy: systematic review and meta-analysis","volume":"102","author":"Shinozaki","year":"2021","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2024.06.038_bib63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13876","article-title":"Randomised clinical trial: efficacy and safety of vonoprazan vs lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials","volume":"45","author":"Miwa","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.06.038_bib64","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00535-019-01587-5","article-title":"Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan","volume":"54","author":"Sugawara","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2024.06.038_bib65","first-page":"135","article-title":"A\u00a0case of severe esophagoduodenal ulcers associating Zollinger-Ellison syndrome successfully treated by vonoprazan fumarate, a novel potassium-competitive acid blocker","volume":"31","author":"Imagawa","year":"2015","journal-title":"Endosc Forum Dig Dis"},{"key":"10.1053\/j.gastro.2024.06.038_bib66","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","article-title":"Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study","volume":"67","author":"Kawai","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.06.038_bib67","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","article-title":"Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study","volume":"67","author":"Mizokami","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.06.038_bib68","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1053\/j.gastro.2024.03.036","article-title":"Comparison of vonoprazan vs intravenous proton pump inhibitor for prevention of high-risk peptic ulcers rebleeding after successful endoscopic hemostasis: a multicenter randomized noninferiority trial","volume":"167","author":"Geeratragool","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.06.038_bib69","article-title":"Heartburn relief is the major unmet need for drug development in gastroesophageal reflux disease: threshold value analysis","author":"Shah","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524052260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524052260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T18:55:45Z","timestamp":1738608945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508524052260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0016508524052260"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2024.06.038","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}